Quick Answer
HOOKIPA Pharma Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $43.95 million for the year ending 2024.
- HOOKIPA Pharma Inc. showed an increase of +118.3% in Revenue From Contract With Customer Excluding Assessed Tax from 2023 to 2024.
- This data is from HOOKIPA Pharma Inc.'s annual report (Form 10-K), filed with the SEC on February 28, 2025.
- XBRL data for this metric is available from 2018 to 2024 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 7 years of available data (2018 to 2024), HOOKIPA Pharma Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 476.0%.
- Historical annual values: Fiscal year 2024: $43.95 million | Fiscal year 2023: $20.13 million | Fiscal year 2022: $14.25 million | Fiscal year 2021: $18.45 million | Fiscal year 2020: $19.58 million | Fiscal year 2019: $11.94 million | Fiscal year 2018: $7.63 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: